Search Results

Nikon Instruments Inc. (Nikon) has developed the SI-PH Phase Condenser, for dedicated use with the ECLIPSE Si biological microscope, improving the efficiency of the ECLIPSE SI.

Curium, a global leader in nuclear medicine, announced the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial.

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology, oncology and immunology, today announced completion of enrollment for two clinical trials evaluating its ropeginterferon alfa-2b-njft (BESREMi®).

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that results from the ECLIPSE study showing the effectiveness of its ShieldTM blood test for detecting colorectal cancer (CRC) in average-risk adults will be published in the March 14 issue of The New England Journal of Medicine.

Nikon Instruments Inc. is pleased to announce the development and launch of the “ECLIPSE Ui”, an integrated microscope-based viewing system designed for both in-person clinical and remote pathological observation.

Nikon Instruments Inc. announced the release of the ECLIPSE Ni-L upright microscope which features specially balanced LED illumination with properties similar to natural light.